I have had this conversation with at least a dozen healthcare AI founders in the past two years: "We are not worried about Epic — they are too slow to ship GenAI features." I understand the sentiment. Epic's development cycles are measured in years. Their design philosophy prioritizes stability and backward compatibility over innovation speed. But this framing fundamentally misunderstands where healthcare AI competition happens and what the relevant moats are.
What Epic Has Built So Far
Epic's GenAI feature set, released incrementally since 2023, is not impressive by startup standards. In-basket message drafting uses a GPT integration to generate draft responses to patient portal messages, reducing average physician response time from 4 minutes to 90 seconds in early studies. Chart summarization compresses a patient's recent visit history into a structured brief for the receiving clinician at transitions of care. Ambient documentation — the AI-assisted SOAP note feature that several pure-play startups (Nuance DAX, Abridge, Suki) built before Epic — shipped in Epic's 2025 update and is now available to every Epic customer.
None of these features is technically state-of-the-art. Nuance DAX had a better ambient documentation product for three years before Epic shipped. Abridge had better summarization. But "technically better" is not the relevant comparison for enterprise software adoption in healthcare. The relevant comparison is "already installed, already trusted, already contracted."
The Distribution Advantage
Epic runs on more than 50% of US hospital beds. Every Epic customer has an existing contract, an existing implementation team, an existing BAA, and an existing upgrade pathway. When Epic ships a new feature, it does not need a new sales cycle — it needs a configuration toggle. A startup selling ambient documentation to an Epic shop is asking that hospital to run a parallel contract, a parallel integration project, a parallel staff training program, and a parallel security review for a product that is now available as a configuration toggle in the system they already pay for. The technical gap has to be enormous to justify that overhead. And for most use cases, it is not.
This is the enterprise-startup translation problem that I see founders get wrong most often. They benchmark their product against Epic's current features and find themselves ahead. But the correct benchmark is "will a health system procurement committee choose a startup over a known vendor with an existing relationship for an AI feature that is 20% better?" The answer is almost never yes. The correct startup strategy is not to compete on features that Epic can ship — it is to identify use cases that Epic will not prioritize for five years, where the outcome improvement is significant enough to justify the startup overhead.
What Startups Should Actually Build
The defensible spaces are the ones Epic cannot or will not serve. Highly specialized clinical workflows for narrow indications (rare disease, subspecialty care, research institutions). Products that require a business model Epic cannot adopt (e.g., outcomes-based contracts where the vendor shares risk on patient outcomes). Markets outside the US hospital system where Epic has limited penetration. And products that require deep integrations with non-Epic data sources — real-world data, genomics, specialty device data — where Epic's data model is a constraint rather than an asset.
The clinician trust dynamic deserves its own mention. Epic's moat is not just distribution — it is accumulated trust with frontline clinicians and IT departments over decades. Healthcare AI startups fail at deployment not because their models are wrong, but because the implementation goes badly, the workflow integration is rough, and the champion physician leaves before the second cohort is onboarded. Epic does not have better AI. But it has a change management playbook that has been run thousands of times. That operational moat compounds slowly and is nearly impossible to replicate quickly.
